The Use of FDG-PET in Patient With Hodgkin Lymphoma: a Population Based Study From Northern Italy

Completed

• Conditions: Histologically Confirmed Classical Hodgkin Lymphoma According to the Current World Health Organisation Classification

• Registration Number: NCT01248000
• Lead Sponsor: Gruppo Italiano Studio Linfomi

Brief Summary

Positron Emission Tomography (PET) represents a step forward in the definition of response to therapy in patients with Hodgkin Lymphoma (HL). In particular the use of PET for the early assessment of response has been described as the most important tool for predicting the risk of disease progression. As no data are available to support the use of early assessment of response for adapting and modifying subsequent treatment, the use of PET should be limited only to patients enrolled in clinical trials. Irrespective of recommendations PET scanning is included in the current management of patients with HL at baseline, mid treatment, end of treatment, and follow-up. So far no study has been performed to verify how PET is currently used in the clinical setting and to assess if and how results of PET scanning are used for supporting treatment and clinical decisions.

Detailed Description

Not available

Study Timeline

• Study Start: 2009-05
• Study Completion: 2010-05
• Status Verified: 2010-11
• Study First Submitted: 2010-11-23
• Study First Submitted QC: 2010-11-24
• Last Update Submitted: 2010-11-24
• Study First Posted: 2010-11-25
• Last Update Posted: 2010-11-25

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 136

Inclusion Criteria

1. Histologically confirmed classical Hodgkin lymphoma according to the current World Health Organisation Classification (nodular sclerosis, mixed cellularity, lymphocyte rich, lymphocyte depleted).
2. Clinical stage I-IV.
3. No previous chemotherapy, radiotherapy or other investigational drug for HL.

Exclusion Criteria

1. None.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Progression-free survival	within 1 month after end of treatment
Overall survival	within 1 month after end of treatment
Disease-free survival	within 1 month after end of treatment

Trial Locations

Locations (1)

Registro Tumori di Modena; 🇮🇹 Modena, Italy